Paper Details

  1. Home
  2. Paper Details

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.

Author: AndreaBenejová, HelenaČoupková, JanaSkřičková, JaromírRoubec, JurajKultan, LeonaKoubková, MarekKonečný, MarkétaČernovská, MartinSvatoň, MichalHrnčiarik, MiladaZemanová, MilošPešek, MonikaŠatánková, RenataChloupková, VítězslavKolek

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effects of crizotinib in patients with advanced anaplastic lymphoma kinase (ALK) -positive non-small cell lung cancer (NSCLC). Crizotinib was effective in treating patients with advanced ALK-positive NSCLC.
Paper Details　
Original Abstract of the Article :
Patients with advanced anaplastic lymphoma kinase (ALK) -positive non-small cell lung cancer (NSCLC) may gain significant benefit from treatment with the first-generation ALK inhibitor crizotinib. This study investigated the effects of crizotinib in advanced ALK-positive NSCLC patients via analyzing...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.14735/amko2018207

データ提供：米国国立医学図書館（NLM）

The Impact of Crizotinib on ALK-Positive Non-Small Cell Lung Cancer

This research investigates the effectiveness of crizotinib, a targeted therapy, in treating patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The researchers analyzed data from the TULUNG registry, a database of lung cancer patients in the Czech Republic, to understand the effects of crizotinib on this specific type of lung cancer.

Navigating the Desert of Lung Cancer Treatment

This research embarks on a journey through the challenging landscape of lung cancer treatment, seeking effective therapies for patients with ALK-positive NSCLC. The researchers examined data from a registry, providing valuable insights into the impact of crizotinib on this specific type of lung cancer. It's like navigating a desert with a compass – understanding the potential benefits and limitations of targeted therapies is crucial for finding effective treatment strategies.

The Potential of Targeted Therapy

The study's findings suggest that crizotinib can offer significant benefits for patients with advanced ALK-positive NSCLC. The researchers observed positive outcomes, indicating the potential of targeted therapies in addressing this specific type of lung cancer. It's like finding a hidden oasis in the desert – targeted therapies can offer hope and relief for patients facing the challenges of lung cancer.

Dr.Camel's Conclusion

This study explores the potential of crizotinib, a targeted therapy, in treating patients with advanced ALK-positive NSCLC. The researchers have provided valuable insights into the impact of this medication, highlighting its potential benefits in addressing this specific type of lung cancer. It's a reminder that ongoing research and the development of innovative therapies are crucial in the fight against lung cancer, and that finding targeted solutions can offer hope and improved outcomes for patients.
Date :
  1. Date Completed 2019-09-06
  2. Date Revised 2019-09-06
Further Info :

Pubmed ID

30441974

DOI: Digital Object Identifier

10.14735/amko2018207

Related Literature

Article Analysis
・Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.